Traumatic brain injury (TBI) is a common cause of death and acquired disability in adults and children. Identifying biomarkers for mild TBI (mTBI) that can predict functional impairments on neuropsychiatric and neurocognitive testing after head trauma is yet to be firmly established. Extracellular vesicles (EVs) are known to traffic from the brain to the oral cavity and can be detected in saliva. We hypothesize the genetic profile of salivary EVs in patients who have suffered head trauma will differ from normal healthy controls, thus constituting a unique expression signature for mTBI. We enrolled a total of 54 subjects including for saliva sampling, 23 controls with no history of head traumas, 16 patients enrolled from an outpatient concussion clinic, and 15 patients from the emergency department who had sustained a head trauma within 24 hr. We performed real-time PCR of the salivary EVs of the 54 subjects profiling 96 genes from the TaqMan Human Alzheimer's disease array.
Concussion clinic
Note. CCPT: concussion clinic patients; ED: emergency department; EDPT: ED head trauma patients; N: no; M: male; F: female; Y: yes; U: unknown. Number of participants in control group, Concussion clinic patient group, and ED head trauma patients, with age range, median age, and gender.
based on clinical symptoms is classified according to the Glasgow Coma Scale: mild (score 13-15), moderate (score 9-10), and severe (score <9; Prins et al., 2013) . Multiple neurochemical processes and cellular pathways are involved in response to the initial insult, including neuron and oligodendrocyte death (Raghupathi, 2004) .
Secondary injuries can occur from cellular and molecular mechanisms responding to the initial injury and can continue long-term (Prins et al., 2013) . Repeated TBI is associated with chronic and sometimes progressive clinical symptoms and neuro-pathological loss of function.
In addition, evidence is growing that moderate to severe or repeated mild TBI (mTBI) incidents could lead to increased risk for Alzheimer's Disease (Heneka et al., 2015; Prins et al., 2013) , and chronic traumatic encephalopathy (CTE; McKee et al., 2009; Mez et al., 2017; Prins et al., 2013) , which is specifically described in patients that have a history of repeated head impacts (Gavett, Stern, Cantu, Nowinski, & McKee, 2010) .
Objective and quantifiable biomarkers are needed to aid in acute TBI diagnosis and help predict those at risk for long-term effects (Rogg et al., 2014) . Recent reviews evaluating moderate to severe TBI highlight the importance of candidate protein biomarkers abundant F I G U R E 1 Transmission electron microscope and western blot images and NanoSight images. (a) Representative transmission electron microscopy of EVs isolated from saliva. EVs were viewed by JEOL Jem 1010 electron microscope (original magnification ×100,000; inset original magnification ×150,000; black lines = 100 nm). (b) Representative western blot analysis of CD63 from saliva EVs.
(MW = standard molecular weight markers). EVs: extracellular vesicles F I G U R E 2 Transmission electron microscope and western blot images and NanoSight images. (a) Salivary EVs size distribution in nanometer (nm) of each control (n = 7), concussion clinic patients (CCPT) (n = 8), and ED head trauma patients (EDPT) (n = 13). (b) EVs concentration for each patient by NanoSight analysis showing the number of EVs per milliliter of saliva derived from controls (n = 7), CCPT (n = 8), and EDPT (n = 13). (c) Mean salivary EVs size with standard deviation by NanoSight analysis showing the mode size of EVs in 1 ml of saliva derived from controls (n = 7), CCPT (n = 8), and EDPT (n = 13). (d) Mean EVs concentration with standard deviation by NanoSight analysis showing the mode size of EVs in 1 ml of saliva derived from controls (n = 7), CCPT (n = 8), and EDPT (n = 13 ABCA1  9·51 ± 3·54  7·99 ± 1·80  0·0239  5·27 ± 6·73   AGER  8·60 ± 4·02  5·92 ± 2·95  0·0203  20·5 ± 32·75   APLP2  7·36 ± 3·24  5·33 ± 2·34  0·0008  17·20 ± 26·99   CDC2  9·62 ± 3·11  11·48 ± 3·70  0·055  6·90 ± 18·48   CSNK1A1  6·25 ± 2·57  3·92 ± 2·01  0·0071  15·9 ± 15·2   CSNK1D  4·80 ± 2·03  3·33 ± 1·58  0·004  5·34 ± 5·6   CTSD  4·68 ± 3·53  2·95 ± 2·27  0·0354  8·06 ± 5·09   GSK3B  6·44 ± 2·74  3·91 ± 1·25  0·0027  6·89 ± 5·87 IL1B
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within neuronal and glial cells (Dash, Zhao, Hergenroeder, & Moore, 2010; Kochanek et al., 2008; Svetlov et al., 2009; Yokobori et al., 2013) .
However, this strategy has not produced relevant and clinically useful results when applied to mTBI. Although numerous works are focused on biomarkers to identify complicated or hemorrhagic mTBI, there is a paucity of similar studies on uncomplicated mTBI (Papa et al., 2016) , which is a more prevalent pathology.
Extracellular vesicles (EVs) were described as a mechanism of cell-to-cell communication. EVs are released by cells, including stem cells and progenitors, and interact with target cells by surfaceexpressed ligands in the transfer of surface receptors, proteins, mRNA, and bioactive lipids (Michael et al., 2010; Papa et al., 2016; Svetlov et al., 2009; Yokobori et al., 2013) . Clinically EVs can be isolated easily and quickly in a noninvasive fashion from multiple bodily fluids including urine and blood (Lakkaraju & RodriguezBoulan, 2008) . Because of the distinctive cargo, EVs can shuttle, as well as the fact that they are tissue specific, they may have a strong clinical application as biomarkers (S. Hu et al., 2008; Skog et al., 2008; Zhong, Taylor, & Whittington, 2010) . In addition, because EVs are membrane-bound, they are not subject to the same degradation that conventional serum biomarkers face. While most studies investigate disease processes with EVs isolated from serum, those that focus on noninvasive EVs biomarkers, such as those present in urine as seen in renal disease (Gonzales et al., 2009; S. Hu et al., 2008) and prostate cancer (Mitchell et al., 2009) In the present study, we report the isolation and characterization of EVs from saliva and for the first time profiled the expression of Alzheimer disease genes in three groups of patients:
acutely head injured emergency department (ED) patients, patients diagnosed with a concussion from an outpatient concussion clinic, and controls. Given the literature surrounding head injury and Alzheimer's disease (Becker, Kapogiannis, & Greig, 2018; Grinberg et al., 2016; Julien et al., 2017; Mendez, Paholpak, Lin, Zhang, & Teng, 2015; Ramos-Cejudo et al., 2018) , we hypothesized that patients with mTBI would express Alzheimer's disease genes at significantly greater levels than controls. Our aim is to determine whether those gene expression profiles changed after mTBI and if the changes of the biomarkers could be potentially used to diagnose mTBI to prognosticate future development of postconcussion syndrome (PCS) or CTE, a disease characterized by tau protein deposition and amyloid beta plagues similar to those seen in Alzheimer's disease (Gavett et al., 2010) .
| MATERIALS AND METHODS
All participants and/or their relatives in addition to normal healthy control subjects gave written informed consent. 
T A B L E 2 (Continued)
Note. CT: cycle threshold; FC: fold change; SD: standard deviation.
(a) Comparison between controls (n = 23) and EDPT (n = 15), columns: gene, controls average ± SD delta CT, EDPT average ± SD delta CT, p value, and average ± SD FC.
(b) Comparison between controls (n = 23) and CCPT (n = 16), Columns: gene, controls average ± SD delta CT, CCPT average ± SD delta CT, p value, and average ± SD FC.
(c) Comparison of gene expression between CCPT and EDPT. Columns: gene, CCPT average ± SD delta CT, CCPT average ± SD FC, EDPT average ± SD delta CT, EDPT average ± SD FC, and the p value. CCPT: concussion clinic patients; EDPT: ED head trauma patients. 
| Patient selection

| Saliva sample collection
According to established protocols (Navazesh, 1993), subjects were directed to orally rinse with cup of water before saliva collection.
Subjects were directed to spit saliva into the test tube every 60 s. At least 5 ml of saliva was collected. One sample was collected per patient. Patients recruited from the ED had their head injury within 24 hr of saliva collection. EVs were isolated via differential ultracentrifugation, and the size and concentration of the EV were analyzed using the NanoSight NS500 instrument (Nanosight, Malvern, UK), transmission electron microscopy (TEM), and western blot analysis.
| Salivary EVs isolation
The protocol was adapted and modified from a previously reported method for salivary EVs isolation (Michael et al., 2010) . Saliva samples were stored at −80°C until they were ready to be analyzed.
The samples were subsequently thawed and centrifuged at 1,500 g for 10 min at 4°C. The supernatant was collected and centrifuged at 17,000 g for 15 min at 4°C. The supernatant was transferred and underwent ultracentrifugation at 120,000 g for 1 hr at 4°C. The remaining pellet was washed with phosphate buffered saline (PBS) and centrifuged at 120,000 g for 1 hr at 4°C. EVs were then resuspended in 500 µl PBS.
2.4 | Measurement of particle size and concentration distribution with NanoSight Nanoparticles in the saliva EVs suspensions were analyzed using the NanoSight NS500 instrument (Nanosight, Malvern, UK). The analysis settings were optimized and kept constant between samples, and each video was analyzed to give the mean, mode, median and estimated concentration for each particle size. Samples were measured at 1:20 dilution, yielding particle concentrations in the region of 1 × 10 8 particles ml −1 as per the manufacturer's recommendations. All samples were analyzed in triplicate. for 20 min. Grids were incubated with 2.5% glutaraldehyde/2% sucrose.
| Transmission electron microscopy
EVs were negatively stained with NanoVan (Nanoprobes, Yaphank, NY) and observed by Jeol JEM 1010 electron microscope (Jeol). 
| Western blot analysis
| Comparison between control and acute ED patients
To assess whether the salivary EVs gene expression profiles in response to head trauma, we used Alzheimer's disease array analysis in salivary EVs. Of the 93 genes from the array, 57 genes were upregulated with an FC higher than two between EDPT and controls.
Wilcoxon sum test shows a statistically different expression between the two groups in 15 genes (Table 2a) with the number of genes with FC above 50, 20, or 2 (FC above 2 considered biologically relevant) is represented in Figure 3a . The 57 genes that were upregulated in EDPT compared with controls is shown in Figure 3b . Gene upregulation (FC > 2) ranged from 45 genes in EDPT5 and EDPT8 to only eight genes in EDPT12.
| Comparison between control and chronic concussion clinic patients
Gene expression profile in outpatient clinic patients (CCPT) showed 56 genes upregulated compared with controls. Wilcoxon rank sum test identified 14 genes with a significant difference between the two groups (Table 2b) 
| Comparison between ED patients and outpatient concussion clinic patients
Wilcoxon sum test of delta CT values shows that 23 Alzheimer's disease genes have a statistically significant difference between the two patient groups (Table 2c) (14.0 ± 9.25), and CTSD (8.5 ± 6.5) (Figure 5b ).
| CONCLUSIONS
There are no biomarkers to help diagnose mTBI or that can predict poor sequelae, such as PCS or CTE. Current biomarkers of brain injuries are obtained from serum or CSF, which is not easily accessible, and focus on more severe head injuries that have associated radiographic abnormalities. On the other hand, identifying a noninvasive biomarker, such as saliva, that can diagnose a concussion or that can identify those at risk for sequelae such as a prolonged recovery or postconcussive syndrome, Alzheimer's disease, or CTE is an exciting possibility. This is the first study isolating
EVs from saliva to identify potential biomarkers for mTBI. In this study, we successfully isolated and identified EVs from saliva as confirmed by TEM and NanoSight analysis of EVs morphology and size and we were able to detect the EVs size distribution and concentration through NanoSight (Figure 2a-2d) . Circulating EVs contain proteins and RNAs, such as mRNA and miRNA (Quesenberry, Aliotta, Deregibus, & Camussi, 2015) . Several studies have suggested using exosome biomarkers for disease diagnosis (Lau & Wong, 2012; Michael et al., 2010; Valadi, Ekstrӧm, Bossios, Sjӧstrand, & Lee, 2007) . The use of exosome cargo as possible markers for disease is a new area of research and EVs to diagnose dementia has been explored previously by Schneider et al. (2018), and Goetzl et al. (2016) .
CTE is a constellation of cognitive, mood, personality, and behavioral alterations that can develop following a single incident or repeated episodes of mTBI (Gavett et al., 2011; Jordan, 2000; Mendez, 1995) . CTE currently can only be diagnosed at autopsy and in vivo biomarker studies are lacking as are longitudinal studies (Asken, Sullan, DeKosky, Jaffee, & Bauer, 2017) . CTE features include extensive tau neurofibrillary tangles, amyloid beta plaques, and some macroscopic abnormalities, such as cerebral atrophy and enlarged ventricles as seen in Alzheimer's disease (Gavett et al., 2010) .
Although the clinical definition is much debated, there is clear overlap between CTE and TBI-induced dementia as experienced by professional boxers (Zetterberg, Smith, & Blennow, 2013) , retired football players, soccer players, hockey, and wrestlers (Gavett et al., 2010) . On this same spectrum of cognitive decline, one could also include Alzheimer's disease, and its cardinal findings of neurofibrillary tangles, tau and amyloid plaques-a striking pathology often found in professional boxers with CTE (Roberts, Allsop, & Bruton, 1990; Tokuda, Ikeda, Yanagisawa, Ihara, & Glenner, 1991) . Studies of individuals who died after a TBI event had amyloid plaques present in all age groups (Johnson, Stewart, & Smith, 2010; Ramos-Cejudo et al., 2018) . However, among patients who died from nonneurological causes, plaques were only seen in elderly individuals (Johnson et al., 2010; Ramos-Cejudo et al., 2018) . Therefore, TBI or repeated head injuries (mTBI) is a strong risk factor for both CTE and Alzheimer's disease (Gavett et al., 2010; Sivanandam & Thakur, 2012 Future studies will correlate the levels of these two candidate biomarkers with neurocognitive testing.
Genes associated with Alzheimer's disease have also been associated with other cerebral/neuronal injury (Ramos-Cejudo et al., 2018; White et al., 2016) . We assayed a number of Alzheimer's disease-related genes that also play a role in neuronal injury, including CAPN1 (Saatman, Creed, & Raghupathi, 2010) , CDK5R1 (Dekker et al., 2014) , CDK5 (Yousuf et al., 2016) , MAPT (Raghupathi, 2004) , GSK3B (White et al., 2016) , and CASP3 (Raghupathi, 2004; White et al., 2016) , which were all upregulated (FC > 2) in the patient populations. These genes are involved in the formation of expression with TBI. CDK5 knockout mice subjected to controlled cortical impact show significantly less injury compared to wild type mice (Yousuf et al., 2016) . CDK5 is consistently elevated in mice subjected to cortical impact (Yousuf et al., 2016) and in hypoxia/ ischemic brain injury in rats (Tan et al., 2015) . This pathway becomes of interest for human TBI diagnosis and for possible therapeutic targets. (Tang, Wu, Zhang, & Su, 2013) . Grading and stratifying TBI severity are routinely based on very subtle examination and neuroimaging findings, which are increasingly difficult to identify acutely (Papa, Edwards, & Ramia, 2015 Delineating the evolution of salivary EVs gene expression after head trauma or diagnosis of concussion will be necessary for a fuller understanding of the significance to these elevated gene expression patterns.
We assert that the determination of mRNA expression on the Taqman ® Alzheimer's disease array may be a valid measure of concussion risk. Larger, longitudinal studies over time will be necessary to determine their overall value in patients with mTBI.
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